Saying No to The Drug Crisis

Brian Klepper In this issue’s guest essay, VIVIO Health’s CEO Pramod John guides us through four sensible drug policy changes and supporting rationales that could make drug pricing much fairer. Reading through it, one is struck by the magnitude of the drug manufacturing industry’s influence over policy, profoundly benefiting that sector at the deep expense […]

NationsHearing’s Interventions Can Decrease Costs Associated with Falling Risk as Confirmed by the Validation Institute

FORT LAUDERDALE, FL—(November 15, 2018) NationsHearing, LLC., a leader in the hearing healthcare industry, announced today that its interventions program has been awarded a Certificate of Validation by the Validation Institute. The validation verifies that NationsHearing’s treatment program can reduce the rate of falling in a senior population and thus, decrease costs for fall-related hospitalizations. […]

Four Policy Solutions That Would Bring Fairness to Drug Pricing

Pramod John Other than the grip that the pharmaceutical industry has on Congress and our state legislatures primarily through their lobbying and control of regulatory bodies, pragmatic fixes to the US drug cost crisis are not that elusive. Here are four straightforward policy solutions that would bring fairness to US drug pricing and parity with […]

The Diagnostic Revolution in Musculoskeletal Care

Ron Donelson No area of clinical over-treatment is as egregious as musculoskeletal (MSk) care. Mis-diagnoses resulting in mis- and over-treatment and wildly excessive spending are especially blatant within low back pain (LBP) care. The conventional LBP clinical exam and imaging diagnostics are unable to identify an accurate diagnosis in 85% of cases. That same inability […]

Getting Noticed As A High Performance Vendor

Brian Klepper All growing health care organizations struggle for visibility. Within the vast health care universe, thousands of companies strive to be noticed as better and different than others competing in the same spaces. Organizational health care buyers face an overwhelming signal-to-noise challenge, trying to discern whether programs improve quality and cost and, if so, […]